Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners III, L.P.(5.3%),VHCP Co-Investment Holdings III, LLC(5.3%), etc.
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(5.7%),Joseph Edelman(5.7%), etc.
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Commodore Capital LP(3.9%),Commodore Capital Master LP(3.9%)
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(1.97%),Deep Track Biotechnology Master Fund, Ltd.(1.97%), etc.
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avoro Capital Advisors LLC(1.7%),Behzad Aghazadeh(1.7%)
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(14.999%),Abigail P. Johnson(14.999%)
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Spyre Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Spyre Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Peter E. Deutsch(6.99%)
Spyre Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sloan Sheldon
Spyre Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Sloan Sheldon
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Burrows Scott L
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(12.963%),Abigail P. Johnson(12.963%)
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Stelzer Laurie
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Milligan Sandra
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fairmount Funds Management LLC
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HENDERSON MICHAEL THOMAS